Vir Biotechnology, Inc. Interest Receivable
Vir Biotechnology, Inc. (VIR) had Interest Receivable of $4.00 million as of 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Balance Sheet › Assets
us-gaap:InterestReceivable · last filed 2024-02-26
- 2023-12-31: Interest Receivable $4.00M.
- 2022-12-31: Interest Receivable $2.50M.
- 2022-09-30: Interest Receivable $2.80M.
- 2021-12-31: Interest Receivable $1.10M.
| Period end | Interest Receivable |
|---|---|
| 2023-12-31 | $4.00M 10-K · filed 2024-02-26 |
| 2022-12-31 | $2.50M 10-K · filed 2024-02-26 |
| 2022-09-30 | $2.80M 10-Q · filed 2022-11-03 |
| 2021-12-31 | $1.10M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |